\u27The eyes have it!\u27 The need to improve awareness and access to early ophthalmological screening for juvenile idiopathic arthritis associated uveitis by Foster HE & Ramanan AV
Newcastle University e-prints  
Date deposited: 
19 November 2009 (embargo until Feb 2010) 
Version of file: 
Author, final 
Peer Review Status: 
Peer reviewd 
Citation for published item: 
Foster HE; Ramanan AV. 'The eyes have it!' The need to improve awareness and access to early 
ophthalmological screening for juvenile idiopathic arthritis associated uveitis. Rheumatology 2009,48 4 
330-331.  
Further information on publisher website: 
http://rheumatology.oxfordjournals.org/cgi/content/extract/48/4/330Further information on 
publisher website: 
Publishers copyright statement: 
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Rheumatology 
following peer review. The definitive publisher-authenticated version is available at: 
http://dx.doi.org/10.1093/rheumatology/kep002 
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
• A full bibliographic reference is made to the original source 
• A link is made to the metadata record in DRO 
• The full text is not change in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
 Robinson Library,  University of Newcastle upon Tyne,  Newcastle upon Tyne. 
NE1 7RU.  Tel. 0191 222 6000 
 
  
 
 
“The eyes have it” 
The need to improve awareness and access to early ophthalmological 
screening for Juvenile Idiopathic Arthritis associated Uveitis 
 
 
Helen Foster and Athimalaipet V Ramanan  
 
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases that differ 
considerably from adult rheumatoid arthritis with different clinical, serological and 
genetic associations [1]. JIA is the commonest cause of acquired chronic disability in 
children and a major cause of visual loss in children as a result of uveitis. The association 
between JIA and uveitis is important because visual complications are common (up to 
40% of children with uveitis) [2, 3], and can result in decreased visual acuity, and also 
blindness from untreated macular oedema, ambylopia and glaucoma. Acute anterior 
uveitis, presenting with a painful red eye is unusual in children and tends to associate 
typically with enthesitis related arthritis and the presence of HLA B27 [4]. The most 
common form of JIA associated uveitis is chronic anterior uveitis, which is typically 
asymptomatic, occurs in all types of JIA with the highest risk being observed in young 
girls (often preschool age) with oligo articular onset and within the first few months of 
onset of arthritis [1]. JIA associated uveitis (accounting for 75 % of all cases of childhood 
uveitis), occurs in 12-38% of children with JIA [4-7], with variation in prevalence 
between JIA subtypes and across different ethnic groups [8]. JIA associated uveitis may 
be bilateral and may indeed precede the onset of joint symptoms; a child presenting with 
visual symptoms usually indicates established eye involvement and has a worse visual 
prognosis [9]. Invariably, in the early stages, chronic anterior uveitis is asymptomatic and 
may only be detected by slit lamp examination by an experienced ophthalmologist.  
 
One of the main prognostic factors associated with adverse visual outcome is the 
presence of uveitis at first ophthalmological evaluation [9, 10]; indeed studies have 
shown that a significant proportion of children with JIA associated uveitis have ocular 
complications including cataract, band keratopathy, posterior synechiae and glaucoma at 
first assessment [3, 11]. Early detection of uveitis is therefore the most important step in 
reducing ocular morbidity and children with suspected JIA should be referred for a slit 
lamp examination as soon as possible and entered into a regular screening programme 
with a period of surveillance which may last several years. Indications for urgent referral 
to an ophthalmologist would be the presence of visual symptoms such as blurring, and 
the presence of an irregular pupil, suspicion of cataract or an absent red reflex. Current 
guidelines for eye screening are based on consensus between the Royal College of 
Ophthalmologists and the British Society for Paediatric and Adolescent Rheumatology 
(http://www.bspar.org.uk/downloads/clinical_guidelines/BSPAR_guidelines_eye_screening_2006.pdf) .  
 
The treatment of JIA associated uveitis depends on the severity of the ocular findings. 
Essentially, topical corticosteroids remain the mainstay of therapy for mild involvement 
and this is often all that is required. Peri-ocular corticosteroids and systemic 
corticosteroids are used for severe exacerbations of uveitis.  Methotrexate (MTX) is used 
increasingly in management of children with moderate to severe uveitis and follows the 
observed trend over the last two decades for earlier and more aggressive 
immunosuppressive treatment of JIA. A significant proportion (at least one third) of 
children with oligo-articular onset JIA will develop an aggressive polyarthritis (termed 
extended oligo-articular JIA) with a guarded articular prognosis. Increasingly many of 
these children will receive methotrexate for their joint disease and despite there being no 
clinical trials to support methotrexate use in JIA associated uveitis, clinical experience 
suggests that this agent is an effective treatment for uveitis.  
 
The frequency of blindness secondary to JIA associated chronic anterior uveitis has 
reduced and generally visual outcomes have improved over the last two decades [5, 6]. 
Several retrospective studies suggest that improved visual outcomes may be related to 
early use of methotrexate [5, 12, 13], although it remains unclear as to whether the 
observed improvement is due to earlier and greater use of methotrexate or improved eye 
screening programmes. For severe uveitis unresponsive to conventional 
immunosuppressive therapy (including methotrexate, cyclosporine or mycophenolate 
mofetil), anecdotal studies suggest that monoclonal antibodies to TNF are effective [14-
18]; case reports and small case series show that infliximab is useful in the management 
of refractory JIA-associated uveitis [19] and recent data suggests that adalimumab may 
also be  efficacious [20, 21]. In contrast, with etanercept, de novo cases of uveitis have 
been reported in children with JIA [22, 23] suggesting that this agent may not prevent the 
onset of uveitis. It is clearly important that all children with JIA associated uveitis are 
managed by ophthalmologists with an interest in paediatric uveitis and working in close 
collaboration with paediatric rheumatologists so that early aggressive immunosuppressive 
therapy can be instituted if required and monitored appropriately 
(http://www.bspar.org.uk/pages/clinical_guidelines.asp)   
 
The commonest presentation of JIA in the UK is oligo-articular onset subtype and these 
children have the highest risk of developing chronic anterior uveitis which is invariably 
asymptomatic in the early stages. Hence all children with suspected JIA (most of 
whom are likely to have oligo-articular onset and therefore have high risk of 
uveitis), are recommended to be referred for ophthalmological screening as soon as 
possible. However, herein lies a major problem. Several studies have shown that there is 
significant delay (often of several months and even years) [10, 24], between the diagnosis 
of JIA and the initial eye screening visit [10, 24]; this observation is likely to reflect the 
fact that most referrals for eye screening are initiated by paediatric rheumatologists and 
delay in access to paediatric rheumatology care is reported in the UK and further afield 
[25, 26]. The reasons for this delay are undoubtedly complex, but likely to be include 
referral pathways as most children with incident JIA do not present directly to paediatric 
rheumatologists but to other health care professionals working within primary and 
secondary care [25].  
 
 Children with musculoskeletal problems are common and present in different guises to 
specialities in primary and secondary care. It is imperative therefore that all doctors are 
able to identify children with suspected JIA, are aware of the association with uveitis and 
the need for urgent referral to specialist paediatric rheumatology care and access to eye 
screening. Currently however, many doctors working in primary and secondary care have 
poor self rated confidence in paediatric musculoskeletal clinical skills [27], largely 
because paediatric musculoskeletal medicine (including clinical skills and knowledge) is 
not part of core training at medical schools [28] and this needs to be addressed. At 
postgraduate level within primary care and general paediatrics, the revised arc GP 
Learning Guides for primary care (www.arc.org.uk), the e-learning for Health (an NHS 
initiative with the Royal College of  General Practitioners (http://www.rcgp.org.uk)  and 
the emergence of Core Competency Frameworks for all general paediatricians 
(http://www.rcpch.ac.uk/Training), will incorporate paediatric musculoskeletal clinical 
skills and knowledge including the association of JIA with uveitis and the importance of 
early referral to specialist care to optimise outcome. However, the current syllabus for 
adult rheumatology (http://www.jrcptb.org.uk) has scant reference to paediatric 
rheumatology, the association of JIA and uveitis is not specifically included and trainees 
emerging from training programmes are not equipped to deliver clinical care for children 
with JIA; this reflects a significant change in the delivery of clinical care over the last  
decade with the emergence of paediatric rheumatology as a sub-specialty and higher 
specialist training within paediatrics. In many parts of the UK however, many established 
adult rheumatologists continue to play an important role in the care of children with JIA 
although involvement within clinical networks with regional paediatric rheumatology 
centres is advocated and the role of adult rheumatologists is likely to shift more towards 
transitional care. In the absence of uniform exposure to paediatric rheumatology within 
current training programmes, and the likelihood of children presenting with JIA to many 
specialities within primary and secondary care, we strongly recommend that trainees in 
adult rheumatology (as well as trainees within orthopaedics, accident and emergency, 
general paediatrics and primary care), are exposed to such clinical networks to gain an 
understanding of the importance of early referral to specialist paediatric rheumatology 
care, and facilitate access to ophthalmological screening. This approach will improve 
earlier detection and treatment of JIA associated uveitis, and ultimately improve visual 
outcomes for these children.   
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